Photo of Donald S. Kaufman,  MD

Donald S. Kaufman, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 726-8689
Fax: (617) 726-8685


dskaufman@partners.org

Donald S. Kaufman, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Professor, Medicine, Harvard Medical School
  • Director, The Claire and John Bertucci Center for Genitourinary Cancers, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research, teaching and clinical interests are all in the area of genitourinary oncology, primarily in the search for more effective treatment for bladder and prostate cancer. My research in bladder cancer is focused on improving treatment options of this common and highly malignant tumor while attempting to improve quality of life by preserving the patient's native bladder.

Publications

Powered by Harvard Catalyst
  • Mitin T, George A, Zietman AL, Heney NM, Kaufman DS, Uzzo RG, Dreicer R, Wallace HJ, Souhami L, Dobelbower MC, Sandler HM, Shipley WU. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. Int J Radiat Oncol Biol Phys 2015; 94:67-74. PubMed
  • Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014; 32:3801-9. PubMed
  • Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G. Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer 2013. PubMed
  • Olumi AF, Kaufman DS, Zietman A, Harisinghani MG, Wu CL. Case records of the Massachusetts General Hospital. Case 25-2013. A 71-year-old man with hematuria and a mass in the bladder. N Engl J Med 2013; 369:660-7. PubMed
  • Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase Lancet Oncol 2013; 14:863-72. PubMed
  • Coen JJ, Paly JJ, Niemierko A, Kaufman DS, Heney NM, Spiegel DY, Efstathiou JA, Zietman AL, Shipley WU. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2013. PubMed
  • Oliva E, Pinheiro NF, Heney NM, Kaufman DS, Shipley WU, Gurski C, Spicer B, Paner GP, Gown AM, Amin MB. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases. Hum Pathol 2013; 44:860-6. PubMed
  • Mitin T, Shipley WU, Efstathiou JA, Heney NM, Kaufman DS, Lee RJ, Zietman AL. Trimodality therapy for bladder conservation in treatment of invasive bladder cancer. Current Urology Reports 2013; 14:109-15. PubMed
  • Kaufman DS, Zietman AL, Dahl DM, Harisinghani MG, Wu CL. Case records of the Massachusetts General Hospital. Case 5-2011. A 65-year-old man with hematuria after treatment for prostate cancer. N Engl J Med 2011; 364:667-75. PubMed
  • Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 2010; 183:2200-5. PubMed
  • Kaufman DS, McDougal WS, Harisinghani MG, Wu CL. Case records of the Massachusetts General Hospital. Case 30-2009. A 77-year-old man with recurrent transitional-cell carcinoma of the ureter. N Engl J Med 2009; 361:1292-9. PubMed
  • Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, Sandler HM. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2009; 27:4055-61. PubMed
  • Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374:239-49. PubMed
  • Wo JY,Shipley WU,Dahl DM,Coen JJ,Heney NM,Kaufman DS,Zietman AL. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guerin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? BJU Int 2009; 104:179-83. PubMed
  • Kaufman DS,Winter KA,Shipley WU,Heney NM,Wallace HJ 3rd,Toonkel LM,Zietman AL,Tanguay S,Sandler HM. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2008; 73:833-7. PubMed
  • Heney NM,Kaufman DS,Shipley WU. Surgery: selective bladder-preserving therapy for muscle-invasive cancer. Nat Rev Clin Oncol 2009; 6:193-4. PubMed
  • Mak RH,Zietman AL,Heney NM,Kaufman DS,Shipley WU. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int 2008; 102:1345-53. PubMed
  • Barry MJ,Kaufman DS,Wu CL. Case records of the Massachusetts General Hospital. Case 15-2008. A 55-year-old man with an elevated prostate-specific antigen level and early-stage prostate cancer. N Engl J Med 2008; 358:2161-8. PubMed
  • Woll PS, Morris JK, Painschab MS, Marcus RK, Kohn AD, Biechele TL, Moon RT, Kaufman DS. Wnt signaling promotes hematoendothelial cell development from human embryonic stem cells. Blood 2007; 111:122-31. PubMed
  • Kaufman DS, McDougal WS, Zietman AL, Young RH. Case records of the Massachusetts General Hospital. Case 18-2007. A 54-year-old man with early-stage prostate cancer. N Engl J Med 2007; 356:2515-20. PubMed
  • Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25:1038-42. PubMed
  • Cohen JH, Schoenbach VJ, Kaufman JS, Talcott JA, Schenck AP, Peacock S, Symons M, Amamoo MA, Carpenter WR, Godley PA. Racial differences in clinical progression among medicare recipients after treatment for localized prostate cancer (United States). Cancer Causes Control 2006; 17:803-11. PubMed
  • Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006; 107:530-5. PubMed
  • Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24:2723-8. PubMed
  • Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS, Islam T, Guimaraes AR, Weissleder R, Harisinghani M. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging 2009; 33:301-5. PubMed
Hide